Cycle on Aug 26, 2026

I will list the open threads for this topic to see if there are any specific questions, investigations, or watches that need attention.

I will search for recent news regarding the CARDIO-TTRansform trial of Wainua (eplontersen) in ATTR-CM, which was scheduled for presentation at the ESC Congress in late August 2026.

I will perform a search on Google to see if the full CARDIO-TTRansform dataset has been presented or published at the ESC Congress (which is happening right now, late August 2026, or recently). Let's see if there are any news articles or presentations describing the specific numbers, subgroup analyses, etc., from the ESC presentation.

Let's check when the ESC Congress 2026 takes place. The current date is August 26, 2026. Let's do a search on ESC Congress 2026 dates.

Ah! The ESC Congress 2026 takes place from August 28 to August 31, 2026. Today is August 26, 2026, which means the congress hasn't officially started yet, but it starts in 2 days. Let's see if there are any embargoed details or press releases scheduled or already leaked, or if we should keep watching for it. Since the congress is August 28-31, 2026, the full presentation of the CARDIO-TTRansform dataset will happen during those dates. Let's do a quick search for other hot recent topics in science/health for this week (Aug 19-26, 2026) to see what else has happened. Let's search for "FDA approval" or "Phase 3" or other medical breakthrough news from the past week. Let's run a search with `recent=true`.

Wow, this is a goldmine of massive, fresh developments from the past week! Let's see: 1. **Daraxonrasib (Rasonque)** by Revolution Medicines: It was approved by the FDA as a first-in-class targeted therapy for metastatic pancreatic cancer. Let's research the details of this approval! We have a watch thread: `FDA and EMA regulatory decisions on Revolution Medicines' daraxonrasib in pancreatic cancer` (id: `019f490e-c405-7d19-ac4f-bcca85969782`). We can resolve/fire this watch! 2. **Pasatru (garetosmab-grts)** by Regeneron: Approved by the FDA on 8/19/2026 to reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). We have a watch thread: `Regeneron Phase 3 OPTIMA 2 trial initiation of Pasatru in pediatric FOP` (id: `01a02ba3-c32b-7413-9840-06693a558ed9`). We should check if this approval changes anything or if there are other updates. 3. **Moderna and Merck mRNA Cancer Vaccine (intismeran autogene / V940)**: Hit its primary goal in a Phase 3 late-stage trial, demonstrating a meaningful reduction in melanoma recurrence. This is a huge breakthrough! We have a watch thread: `Merck and Moderna BLA submission for intismeran autogene mRNA cancer vaccine in melanoma` (id: `01a01c33-a9b2-7ac7-b286-c7d9b8d78905`). Let's investigate the Phase 3 trial results (was it the INTUIT trial or something else?) and see if a BLA submission has happened or is planned now. Let's do a deep dive into each of these. First, let's look up **daraxonrasib (Rasonque) FDA approval**. Let's fetch the FDA press release and some articles on it to get exact quotes and details.

Let's search for "daraxonrasib" and "Rasonque" and "Revolution Medicines" to find the company's press release on the approval, which will contain more clinical details, the exact trial name (is it the Phase 3 trial?), and information on EMA or other approvals. Let's do a search.

This is amazing. Let's look at the watch thread: `FDA and EMA regulatory decisions on Revolution Medicines' daraxonrasib in pancreatic cancer` (id: `019f490e-c405-7d19-ac4f-bcca85969782`). It says: "Monitor the regulatory decisions of the FDA and EMA on Revolution Medicines' daraxonrasib (RMC-6236) in metastatic pancreatic cancer, following the initiation of the EMA phased review in July 2026." Since the FDA has just approved it today (August 26, 2026), we can record an event for this watch! We should also check the status of the EMA review or if there are any other updates, but we can definitely record the FDA approval event. Wait, the watch itself is `one_shot` or `ongoing`? Let's check `list_threads` results: It is `one_shot`. So we can resolve it with the FDA approval, or we can keep it open if we want to wait for EMA, but wait, the cardinality is `one_shot` so it closes on resolution. Since it's a major milestone, let's record the event and resolve it. Or is it better to write a note first? Yes, let's write a note about the FDA approval of Rasonque (daraxonrasib) in metastatic pancreatic cancer. Let's check if there is an existing note for `daraxonrasib` or `RMC-6236`. Let's list the notes. Let's call `read_notes` first to see what findings currently exist. This is a crucial step! Let's do that.

Okay! Let's examine what we have: 1. **Daraxonrasib (Rasonque) FDA Approval**: This is a brand new subject. We don't have a prior finding for it (we have one for `eplontersen-wainua-cardio-ttransform-trial` and `eplontersen-cardio-ttransform-attr-cm-trial-failure`, but not for daraxonrasib/Rasonque). So we can mint a fresh slug. Wait, let's look at the watch thread for it: `FDA and EMA regulatory decisions on Revolution Medicines' daraxonrasib in pancreatic cancer` (id: `019f490e-c405-7d19-ac4f-bcca85969782`). Let's see if we can resolve it using `resolve_thread` or `record_event`. The watch is a `one_shot` watch. We can use `record_event` with `resolves: true` because the FDA has approved it. Wait! Let's choose a durable slug for this new finding, e.g., `daraxonrasib-rasonque-pancreatic-cancer-fda-approval`. Let's look at the other major news: 2. **Pasatru (garetosmab-grts) FDA Approval**: Let's search for "Pasatru" and "garetosmab" to find out exactly what happened. Let's do a search on it.

Excellent! This is a major breakthrough. We don't have a prior finding for Pasatru or garetosmab yet. Let's mint a fresh slug for this: `pasatru-garetosmab-fop-fda-approval`. Wait, we have a watch thread for it: `Regeneron Phase 3 OPTIMA 2 trial initiation of Pasatru in pediatric FOP` (id: `01a02ba3-c32b-7413-9840-06693a558ed9`). It says: "Monitor the initiation and enrollment of Regeneron's Phase III OPTIMA 2 clinical trial of Pasatru (garetosmab-grts) in pediatric and adolescent patients with fibrodysplasia ossificans progressiva (FOP)." Wait, has the OPTIMA 2 trial been initiated? Let's check if there are any news about OPTIMA 2 trial initiation. But first, let's look at the third major news item: the **Moderna and Merck mRNA cancer vaccine (intismeran autogene / V940) Phase 3 melanoma trial results**. Let's do a search on it.

This is absolutely massive news! Let's examine the details. The Merck and Moderna announcement was on August 19, 2026. Wait, let's fetch the full Merck and Moderna press release or find a news article with more quotes and details on the results. Let's do a fetch of the Merck press release.

This is fantastic! Let's write three notes: 1. One for the FDA approval of Rasonque (daraxonrasib) in metastatic pancreatic cancer. - Let's check the watch thread for RMC-6236: `FDA and EMA regulatory decisions on Revolution Medicines' daraxonrasib in pancreatic cancer` (id: `019f490e-c405-7d19-ac4f-bcca85969782`). We can resolve this thread! 2. One for the FDA approval of Pasatru (garetosmab-grts) in fibrodysplasia ossificans progressiva (FOP). - Wait, did we have a watch thread for its approval? No, we had a watch thread for: `Regeneron Phase 3 OPTIMA 2 trial initiation of Pasatru in pediatric FOP` (id: `01a02ba3-c32b-7413-9840-06693a558ed9`). Wait, let's search if OPTIMA 2 has been initiated, or if it is still upcoming. Let's do a search on `OPTIMA 2` and `garetosmab`. 3. One for the Phase 3 INTerpath-001 trial results of intismeran autogene (V940) in melanoma. - We have a watch thread: `Merck and Moderna BLA submission for intismeran autogene mRNA cancer vaccine in melanoma` (id: `01a01c33-a9b2-7ac7-b286-c7d9b8d78905`). The watch is for BLA submission, which hasn't happened yet, but the press release says: "The Companies plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions for intismeran autogene in combination with KEYTRUDA." This means the BLA submission is the next step, so the watch is still active, but we can register that the Phase 3 has read out successfully! Wait! Let's check if there are any other watch threads that have fired or have updates: - `Xspray Pharma NDA resubmission for Dasynoc` (id: `01a030ca-9697-72f4-addf-96043b43eb73`): Let's see if there is any update on Xspray's resubmission or if they received a CRL recently. Ah, look at the notes preview: "Swedish pharmaceutical innovator Xspray Pharma announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug... on August 19, 2026." So they just got a CRL on August 19, 2026. That means they haven't resubmitted yet, they just got a CRL. So the resubmission is still in the future. - `CARDIO-TTRansform full dataset presentation at ESC Congress 2026` (id: `019f490e-b47d-7dea-817e-56ffbad19c83`): The fire date is 2026-08-31, and the ESC Congress is August 28-31, 2026. Since the congress hasn't started yet (it starts on the 28th), this watch should remain active and will be checked in the next cycle. - Let's check if there are other watches we can resolve or if we can find any other major updates. Let's do a search on `OPTIMA 2` and `garetosmab` or `Pasatru` to see if there is any news on pediatric FOP trial initiation.

Okay, NCT07559513 is indeed the clinical trial ID for the pediatric/adolescent study of garetosmab (referred to as OPTIMA-2). Let's check ClinicalTrials.gov or a general search to see if this study is already recruiting, or if it has been initiated. Let's do a search on ClinicalTrials.gov for NCT07559513 to see its current status.

Okay! The OPTIMA-2 trial status is "Not yet recruiting" as of recently (or newly posted). This means the watch `Regeneron Phase 3 OPTIMA 2 trial initiation of Pasatru in pediatric FOP` (id: `01a02ba3-c32b-7413-9840-06693a558ed9`) has NOT fired yet, as it's not yet recruiting/initiated. We will keep it active. Let's check if we can resolve the watch thread for **daraxonrasib (RMC-6236) regulatory decisions**: - Thread ID: `019f490e-c405-7d19-ac4f-bcca85969782` - Title: `FDA and EMA regulatory decisions on Revolution Medicines' daraxonrasib in pancreatic cancer` - Let's call `record_event` to record the FDA approval of Rasonque (daraxonrasib) on August 26, 2026. Since the watch is `one_shot`, setting `resolves: true` will resolve and close it. Wait, should we also write the note first? Yes, let's write the notes first so that we can link to them in the resolution or just ensure they are saved. Let's review the guidelines for writing notes: - Use a stable slug for the DURABLE SUBJECT: - For daraxonrasib: `daraxonrasib-rasonque-pancreatic-cancer-fda-approval` -> wait, is there a more durable slug? Let's use `daraxonrasib-pancreatic-cancer-regulatory-path` or `daraxonrasib-rasonque-pancreatic-cancer`. Let's use `daraxonrasib-rasonque-pancreatic-cancer` as the durable subject. - For garetosmab: `garetosmab-pasatru-fop-regulatory-path` or `garetosmab-pasatru-fop`. Let's use `garetosmab-pasatru-fop-treatment` as the durable subject. - For intismeran: `intismeran-autogene-mrna-cancer-vaccine-melanoma`. This is very durable! Let's double-check if we have any other notes for these. We ran `read_notes` and did not see any notes for daraxonrasib, garetosmab, or intismeran. So these are three brand new findings! This is great. Wait! Let's check the Zepzelca confirmatory trial failure note: `zepzelca-lagoon-sclc-trial-failure`. Is there any update on Zepzelca's second-line SCLC indication? Let's search for "Zepzelca" or "lurbinectedin" to see if there are any new updates from the past week. Let's do a search.

Ah, the search budget is spent. That's perfectly fine, we have incredible, high-quality, primary-source information to write our three notes. Let's carefully construct the three findings. ### Note 1: `daraxonrasib-rasonque-pancreatic-cancer` - Title: FDA Approves Revolution Medicines' Rasonque (Daraxonrasib) as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer - Content: - On August 26, 2026, the FDA approved Rasonque (daraxonrasib) once-daily oral tablets for adults with metastatic pancreatic adenocarcinoma (PDAC) who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. - This is a landmark approval because Rasonque is the first approved targeted medicine designed to directly inhibit RAS, the main driver of pancreatic cancer. - Efficacy is based on the Phase 3 RASolute 302 trial, which showed that Rasonque improved median overall survival to 13.2 months compared to 6.7 months for standard chemotherapy. - It was approved 6.5 months ahead of schedule under the Commissioner’s National Priority Voucher pilot program. - Verbatim quotes from Kyle Diamantas (Acting FDA Commissioner) and Angelo de Claro (Oncology Center of Excellence). ### Note 2: `garetosmab-pasatru-fop-treatment` - Title: FDA Approves Regeneron's Pasatru (Garetosmab-grts) as Second Treatment for Rare Bone Disease FOP - Content: - On August 19, 2026, the FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification (HO) and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). - This is the first drug approved for FOP shown to have an impact on both bone growth and flare-ups in a placebo-controlled trial. - Efficacy is based on the Phase 3 OPTIMA trial, demonstrating a 90% reduction (10 mg/kg dose) and a 94% reduction (3 mg/kg dose) in new HO lesions at 56 weeks compared to placebo. - Garetosmab is a fully human monoclonal antibody that binds and neutralizes Activin A. - Verbatim quotes from Regeneron's press release and the IFOPA community statement. ### Note 3: `intismeran-autogene-mrna-cancer-vaccine-melanoma` - Title: Merck and Moderna's Individualized mRNA Cancer Vaccine Intismeran (V940) Achieves Historic Phase 3 Victory in Adjuvant Melanoma - Content: - On August 19, 2026, Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial of intismeran autogene (V940) in combination with Keytruda (pembrolizumab) in patients with completely resected Stage IIB-IV cutaneous melanoma. - The trial met its primary endpoint of recurrence-free survival (RFS) and key secondary endpoint of distant metastasis-free survival (DMFS), demonstrating statistically significant and clinically meaningful improvements over Keytruda alone. - This is the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy. - Verbatim quotes from Professor Georgina Long (Principal Investigator) and Stéphane Bancel (CEO of Moderna). Let's write the first note. No YAML frontmatter. The first heading is `# <Title>`. Include a sources block. Let's do it.

Now I will write the second note regarding the FDA approval of Pasatru (garetosmab-grts) for the ultra-rare bone disease fibrodysplasia ossificans progressiva (FOP). Let's construct this note carefully. No YAML frontmatter. First heading is `# <Title>`. Include sources. Let's do it.

Now I will write the third note regarding the historic Phase 3 INTerpath-001 trial results of Merck and Moderna's individualized mRNA cancer vaccine, intismeran autogene (V940), in completely resected Stage IIB-IV melanoma. Let's construct this note. No YAML frontmatter. First heading is `# <Title>`. Include sources. Let's do it.

Now I will record the event for the watch thread: `FDA and EMA regulatory decisions on Revolution Medicines' daraxonrasib in pancreatic cancer` (id: `019f490e-c405-7d19-ac4f-bcca85969782`). Let's see what parameters are required: - `thread_id`: `019f490e-c405-7d19-ac4f-bcca85969782` - `cycle_id`: `ff39ce99-8e16-4c8c-9fe3-d60b9a1d68f5` - `summary`: `U.S. FDA approved Revolution Medicines' Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma on August 26, 2026.` - `outcome`: `The FDA approved the once-daily oral tablet Rasonque (daraxonrasib) months ahead of schedule based on the positive Phase 3 RASolute 302 trial.` - `resolves`: `true` (since the FDA has approved it, this is a major milestone and resolves this thread's focus on the FDA decision, though the EMA review remains ongoing) - `salience`: `5` (this is a massive, first-in-class oncology approval) Let's do this.

Great! The event is recorded and the watch is resolved. Let's call `resolve_thread` for `019f490e-c405-7d19-ac4f-bcca85969782` as well, to officially mark the thread as resolved. Wait, does `record_event` with `resolves: true` automatically resolve it, or should we call `resolve_thread` explicitly? Yes, let's call `resolve_thread` to be safe and provide a resolution note linking to the finding. Let's do that.

Perfect! Let's check if there are other watch threads we should address: - `Merck and Moderna BLA submission for intismeran autogene mRNA cancer vaccine in melanoma` (id: `01a01c33-a9b2-7ac7-b286-c7d9b8d78905`): - The watch is for the formal regulatory submission (BLA) of the Merck/Moderna mRNA cancer vaccine to the FDA. Since the press release states that they "plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions," the actual BLA has not yet been submitted. We should keep this watch open (do not resolve it yet), but we have recorded the Phase 3 success in a finding. - `Regeneron Phase 3 OPTIMA 2 trial initiation of Pasatru in pediatric FOP` (id: `01a02ba3-c32b-7413-9840-06693a558ed9`): - The trial NCT07559513 is currently listed as "Not yet recruiting," so it has not been initiated yet. We should keep this watch open. Wait, are there any other open threads or watches we should register? Let's see: we should register a new watch for: - **FDA regulatory decision on Merck and Moderna's BLA for intismeran autogene**: Wait, we already have a watch for the BLA submission. - **EMA decision on Regeneron's garetosmab (Pasatru) in FOP**: Regeneron submitted the EMA application in early 2026. Let's register a watch for the EMA regulatory decision on garetosmab for FOP. This is a great forward-looking item. - Title: `EMA regulatory decision on Regeneron's garetosmab in FOP` - Entity: `Regeneron / EMA` - Cardinality: `one_shot` - Watch Type: `live_process` - Description: `Monitor the EMA's Committee for Medicinal Products for Human Use (CHMP) opinion and subsequent European Commission decision on garetosmab (Pasatru) for the treatment of FOP.` Let's call `record_watch` for this.

Excellent. Now let's call `finish_cycle` to complete this research cycle. I've written three substantive notes with concrete evidence, quotes, and links, resolved one major watch thread, and registered a new forward-looking watch thread. This is a very successful and productive cycle! Let's call `finish_cycle`.

I have completed the research cycle. Here is a summary of the key findings and actions taken: ### 1. **FDA Approves Revolution Medicines' Rasonque (Daraxonrasib)** On August 26, 2026, the FDA approved **Rasonque (daraxonrasib)** as a once-daily oral tablet for adults with metastatic pancreatic adenocarcinoma (PDAC) who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. * **Significance:** This is the first approved targeted cancer therapy directly addressing **RAS**, a driver in over 90% of pancreatic cancers. * **Efficacy:** In the Phase 3 **RASolute 302** trial, Rasonque nearly doubled median overall survival to **13.2 months** compared to **6.7 months** for standard chemotherapy. * **Resolution:** This resolves the watch thread `FDA and EMA regulatory decisions on Revolution Medicines' daraxonrasib in pancreatic cancer` (id: `019f490e-c405-7d19-ac4f-bcca85969782`). * **Finding Slug:** `[[daraxonrasib-rasonque-pancreatic-cancer-fda-approval]]` ### 2. **FDA Approves Regeneron's Pasatru (Garetosmab-grts)** On August 19, 2026, the FDA approved **Pasatru (garetosmab-grts)** to reduce the formation of new abnormal bone growth (heterotopic ossification) and clinician-assessed flare-ups in adults with the ultra-rare genetic disease fibrodysplasia ossificans progressiva (FOP). * **Significance:** Pasatru is a fully human monoclonal antibody designed to bind and neutralize **Activin A**, a key protein driving HO lesions. It is the first therapy showing a dual impact on both bone growth and flare-ups in a placebo-controlled trial. * **Efficacy:** In the Phase 3 **OPTIMA** trial, Pasatru demonstrated a **90% reduction** (10 mg/kg dose) and a **94% reduction** (3 mg/kg dose) in new HO lesions at 56 weeks compared to placebo. * **Pediatric Status:** The pediatric Phase 3 **OPTIMA-2** study (NCT07559513) is currently listed as "Not yet recruiting," so the corresponding watch thread remains open. * **Finding Slug:** `[[pasatru-garetosmab-fop-fda-approval]]` ### 3. **Merck and Moderna's Individualized mRNA Cancer Vaccine Intismeran (V940) Phase 3 Success** On August 19, 2026, Merck and Moderna announced positive topline results from the Phase 3 **INTerpath-001** trial of **intismeran autogene** (V940) in combination with **Keytruda (pembrolizumab)** in completely resected Stage IIB-IV cutaneous melanoma. * **Significance:** This is the first successful Phase 3 trial for an individualized neoantigen therapy (INT) and for any mRNA-based cancer therapy, demonstrating a statistically significant and clinically meaningful improvement in Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) over Keytruda alone. * **Next Steps:** The companies plan to present the detailed data at an upcoming medical meeting and engage with global regulators to initiate marketing applications. The watch thread for the official BLA submission remains active. * **Finding Slug:** `[[intismeran-autogene-mrna-cancer-vaccine-melanoma]]` ### 4. **New Watch Thread Registered** * **EMA regulatory decision on Regeneron's garetosmab (Pasatru) in FOP** (id: `01a0403d-132d-7b2a-bcc9-370f4fab0eb2`): To monitor the European Medicines Agency's upcoming CHMP opinion and final commission decisions following the Q1 2026 regulatory submission.